Studier, hvor der blev anvendt orale antidiabetika i kombinationsterapi med Levemir resulterede i en 61- 65% lavere risiko for mindre natlig hypoglykæmi sammenlignet med NPH- insulin.
In trials with the use of OAD-insulin combination therapy Levemir treatment resulted lower risk of minor nocturnal hypoglycaemia compared to NPH insulin.